Telix | ProstACT™ Global

# Has your prostate cancer progressed after prior treatment?

**You may be able to take part in a study for patients with metastatic castration-resistant prostate cancer (mCRPC).**

## What is this study?

- This study is evaluating a targeted radiation treatment called TLX591 (Lu177) for people with metastatic castration-resistant prostate cancer (mCRPC).
- The treatment targets PSMA, a protein found on prostate cancer cells, and is designed to deliver radiation directly to those cancer cells.
- The goal of this study is to learn whether adding TLX591 to standard treatment may help treat metastatic prostate cancer better than standard treatment alone.

## Who can participate?

**You may qualify if you:**

- Are male and 18 years or older
- Have prostate cancer confirmed by biopsy
- Have metastatic castration-resistant prostate cancer (mCRPC)
- Have received at least 12 weeks of treatment with one type of hormone therapy (called an ARPI)
- Have PSMA-positive disease confirmed by a PSMA PET scan

## What will happen in this study?

### Step 1

**Screening tests**
Bloodwork and other health checks

### Step 2

**Random assignment**
Participants are randomly assigned to receive either:
- TLX591 plus standard of care OR
- Standard of care alone

### Step 3

**PSMA PET scan**
Single intravenous dose of TLX591

### Step 4

**Study treatment visits**
If you receive TLX591:
- First dose on Day 1
- Second dose on Day 14

If you receive standard of care treatment your doctor will inform you of your treatment visits.

### Step 5

**Follow-up visits**
Regular check-ups and safety monitoring

## Glossary

**Androgen receptor pathway inhibitor (ARPI)**
A hormone therapy that helps keep prostate cancer from growing or spreading.

**Metastatic prostate cancer**
Prostate cancer that has spread to other parts of the body.

**Metastatic castration-resistant prostate cancer (mCRPC)**
Prostate cancer that has spread and continues to grow despite treatment.

**Prostate-specific membrane antigen (PSMA)**
A protein found on many prostate cancer cells that can help doctors find and treat the cancer.

**PSMA PET scan**
An imaging test that helps doctors find prostate cancer cells in the body.

**TLX591**
An investigational treatment designed to deliver radiation directly to prostate cancer cells that have the PSMA target.

**Screening**
Tests done before starting the study to confirm whether you qualify, including checking that your cancer has the PSMA target.

## Questions to Ask Your Doctor

1. Why should I consider joining this study now?
2. What treatment options do I have if I do not join this study?
3. What does it mean if my cancer is PSMA-positive?
4. What are the possible risks and benefits of participating in this study?
5. How often are the visits, and how much time will each visit take?
6. What tests or scans will be required during the study?

**Scan Here to Learn More**